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Normalbraintissuefrom28individuals and50gliomasamples wereanalyzed byreal-timeQuantitativeMethylation-Speciﬁc PCR
(QMSP). Data from this analysis were compared with results obtained on the same samples by MSP. QMSP analysis demonstrated
a statistically signiﬁcant diﬀerence in both methylation level (P = .000009 Mann Whitney Test) and frequencies (P = .0000007,
Z-test) in tumour samples as compared with normal brain tissues. Although QMSP and MSP showed similar sensitivity, the
speciﬁcity of QMSP analysis was signiﬁcantly higher (93%; CI95%: 84%–100%) as compared with MSP (64%; 95%CI: 46%–
82%). Our results suggest that QMSP analysis may represent a powerful tool to identify glioma patients that will beneﬁt from
alkylating agents chemotherapy.
Copyright © 2009 Paola Parrella et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Gliomas are the most common form of primary intracranial
malignancy. High-grade gliomas like glioblastoma multi-
forme (GBM, WHO grade IV) are the most frequent lesions
encountered with a median survival rate of less than 1 year
[1]. Radiotherapy alone or in association with chemother-
apeutical agent is the current option for the treatment
of gliomas. Recent clinical trials have demonstrated that
the association of radiotherapy to treatment with procar-
bazine, lomustine, and vincristine can improve progress-free
survival and treatment with temozolomide even improves
o v e r a l ls u r v i v a l[ 2–4]. These results have provided some
guide to establish optimal treatment choice for gliomas,
but their ﬁndings have also highlighted the heterogeneity in
response to the treatment in the same patient subgroup.
The epigenetic silencing of the O6-methylguanine-DNA-
methyltransferase (MGMT) gene by promoter hyperme-
thylation is emerging as a clinically relevant predictor of
response to treatment in glioma patients. MGMT pro-
moter hypermethylation can be detected in approximately
half of gliomas and it is associated with longer overall2 Journal of Biomedicine and Biotechnology
survival in patients who receive alkylating chemotherapy
in association with radiotherapy [5–7]. Alkylating agents
induce cell death by forming cross links between adjacent
DNA strands through the alkylation of the O6 position
of guanine. Transcriptional active MGMT rapidly removes
the alkyl adducts preventing the formation of cross links
thereby causing resistance to alkylating drugs [8]. MGMT
promoter hypermethylation with consequent loss of MGMT
protein expression reduces the DNA repair activity of
glioma cells overcoming resistance to alkylating agents
[5].
To translate this ﬁnding into clinic there is the need
for molecular diagnostic tools that can be reliably applied
on a large scale of clinical samples. Several methods for
assessing promoter methylation status have been reported
[9–16], but the most widely used is Methylation-Speciﬁc
PCR (MSP) analysis after bisulphite treatment [17]. This
method however is not quantitative and bears a signiﬁcant
risk of false positive and false negative results [12, 18, 19].
Real-time Quantitative Methylation-Speciﬁc PCR (QMSP)
has been used to detect promoter hypermethylation of
several genes, including MGMT, in primary tumours and
bodily ﬂuid from cancer patients [20–30]. We validated
a QMSP approach for determining methylation status of
the MGMT promoter in 50 gliomas (28 formalin-ﬁxed
paraﬃn-embedded samples and 22 snap-frozen specimens)
from 46 patients. Since promoter hypermethylation is often
detected also in normal tissues [31, 32], we determined the
speciﬁcity of the assay in normal brain tissues obtained from
autopsies. The performance of QMSP analysis was compared
to conventional Methylation-Speciﬁc PCR (MSP).
2.MaterialsandMethods
2.1. Patients and Samples. A total of 50 tumour samples
from 46 patients were obtained from the Department
of Pathology and stored in accordance with institutional
policies. Of those tumours, 28 were formalin-ﬁxed paraﬃn-
embedded (FFPE) samples and 22 snap-frozen specimens.
All patients were treated by surgery at the Department of
Neurosurgery of the IRCCS “Casa Sollievo della Soﬀerenza”
San Giovanni Rotondo (FG) between 2006 and 2008. After
surgery, patients received chemotherapy with the alkylating
agent temozolomide at a dose of 75mg per square meter
of body surface area daily during standard fractionated
radiotherapy (60Gy) for 6-7 weeks. The median age of
this cohort was 58 years (Interquartile Range, IQR 47–63
years) and median follow up time was 11 months (IQR
4.75–18months) Pathological diagnosis included 35 (76%)
glioblastoma multiforme (20 males and 15 females), 9
(20%) astrocytomas (4 males and 5 females), and 2 (4%)
oligodendrogliomas (2 males). Paired primary and recurrent
tumour specimens were available for three patients (G3, G8,
andG24).Ascontrol28snap-frozenhistologicallyconﬁrmed
normal brain tissues obtained from autopsies were analyzed
(Median age 64 years; IQR 53–75 years).
2.2. DNA Extraction and Bisulphite Conversion. Sections, 5-
μm-thick, were cut from paraﬃn blocks or OCT embedded
frozen specimens to ensure that tumour samples contained
at least 70% cancer cells and to conﬁrm that tissues obtained
from autopsies were histological normal. Tumour specimens
were then carefully dissected, under a microscope from
six to ten 12-μm-thick sections to enrich for areas that
contained tumour cells. FFPE samples were subsequently
placed in xylene to remove the paraﬃn as described previ-
ously [33]. Tumour and normal tissues were digested with
SDS/proteinase K for 24 hours at 48◦C, and DNA was
extracted with phenol/chloroform [34]. DNA concentration
was quantiﬁed using the Nanodrop spectrophotometer.
DNA extracted from normal brain or tumour samples
was subjected to bisulphite treatment and DNA puriﬁcation
using the Epitect Bisulﬁte kit (Qiagen Sci, Md, USA)
according to manufacturer instruction. Bisulphite-modiﬁed
DNA from the same treatment was used as template
for ﬂuorescence-based real-time quantitative Methylation-
Speciﬁc PCR (QMSP) and conventional Methylation-
Speciﬁc PCR (MSP).
2.3. Quantitative Methylation-Speciﬁc PCR (QMSP).
Real-time PCR was performed for MGMT using the
following primer/probe set [22]: forward 5
 -CGAATATAC
TAAAACAACCCGCG-3
 , reverse 5
 -GTATTTTTTCGG
GAGCGAGGC-3
 ; probe 5
 -FAMAATCCTCGCGATACG
CACCGTTTACGTAMRA-3
 , yielding a 122bp amplicon.
As reference gene a primer/probe set speciﬁc for the
unmethylated promoter region of the ACTB gene was
used [22].: forward 5
 -TGGTGATGGAGGAGGTTT
AGTAAGT-3
 ; reverse 5
 -AACCAATAAAACCTACTCCTC
CCTTAA-3
 ; probe 5
 -FAMACCACCACCCAACACACA
ATAACAAACACATA-MRA-3
 , yielding an amplicon size
of 133bp Leukocyte DNA from a healthy blood donor
was methylated in vitro with excess SssI methyltransferase
(New England Biolabs Inc., Beverly, Mass, USA) to generate
completely methylated DNA. Serial dilutions (90-0.009ng)
of this DNA were used to construct calibration curves for
MGMT and ACTB genes.
Ampliﬁcation reactions were carried out in triplicate
in a volume of 20μL that contained 50ng bisulphite-
modiﬁed DNA, 600nM forward and reverse primers,
200nM probe, 0.6U of Platinum Taq polymerase (Invitro-
gen, Inc., Rockville, Md, USA), 200μM each of dATP, dCTP,
dGTP, dTTP, and 2μLo fP C Rb u ﬀer [35]. PCR conditions
were as follows: one step at 95◦C for 3 minutes, 50 cycles
at 95◦C for 15 seconds, and 60◦Ct o6 2 ◦Cf o r1m i n u t e .
PCR reactions were performed in 96-well plates in a 7900
Sequence detector (Applied Biosystems, Carlsband, Calif,
USA) and were analyzed by SDS 2.1.1 software (Applied
Biosystems, Carlsband, Calif, USA). Each plate included
calibration curves for the ACTB and MGMT genes, patient
DNA samples, positive (CpGenome Universal Methylated
DNA, Serologicals Corp., Norcross, Ga, USA) and negative
(UniversalUnmethylatedDNA,SerologicalsCorp.,Norcross,
Ga, USA) controls, and multiple water blanks. The relative
levelofmethylatedDNAwasdeterminedasaratioofMGMT
to ACTB and then multiplied by 1000 for easier tabulation
(average value of triplicates of gene of interest/average value
of triplicates of ACTB × 1000). For each sample QMSPJournal of Biomedicine and Biotechnology 3
analysis was repeated on three separate plates and median
values were considered for statistical analyses.
2.4. Methylation-Speciﬁc PCR (MSP) Analysis. Conventional
MSP was carried out as described previously [36]. A PCR
reaction for the ACTB gene promoter region not containing
CpG was also performed as control of the bisulphite
conversion. Forward and reverse primers for the bisulphite-
converted methylated sequence of MGMT and ACTB were
the same nonﬂuorogenic oligonucleotides used for QMSP.
PCR conditions were as follows: 35 cycles at 95◦Cf o r1
minute, 64◦Ca n d7 2 ◦C for 1 minute. For each PCR reaction
CpGenome Universal Methylated DNA (Serologicals Corp.,
Norcross, Ga, USA) was used as positive control, and
Universal Unmethylated DNA (Serologicals Corp., Norcross,
Ga, USA) was used as negative control. PCR products were
run on a 3% Agarose gel stained with ethidium bromide and
visualized at UV light.
2.5. Statistical Analyses. Multiple comparisons among nor-
malbraintissues,formalin-ﬁxedparaﬃn-embeddedsamples
(FFPE) and snap-frozen tumour specimens, in terms of
MGMT methylation levels, were performed through the
nonparametric Kruskall-Wallis and Dunn tests. Results from
these analyses allowed also to the application of the Mann-
Whitney test. Nonparametric analysis was implemented
because results of Kolmogorov-Smirnov and Shapiro tests
rejected the Gaussian distribution assumption. The optimal
cutoﬀ in terms of sensitivity and speciﬁcity for detecting
MGMT methylation by Quantitative Methylation-Speciﬁc
PCR (QMSP) was determined by drawing the ROC curve
using methylation levels in normal brain tissues and tumour
samples. The area under the ROC curve, computed numer-
ically and tested for statistically signiﬁcance, was assumed
as a measure of goodness of the test. The ROC curves,
built separately for the FFPE and snap-frozen tumour group,
were compared by testing the diﬀerence between the two
areas under the ROC curves using the Gaussian approxi-
mation. Promoter methylation frequencies determined, in
each group, by MSP and QMSP were compared using the
Z-test for proportions’ diﬀerence. To measure the degree
of concordance of the results between QMSP and MSP the
κ statistic and its 95% conﬁdence interval (95%CI) were
calculated. κ values were interpreted as follows: κ = 0.00
no agreement; κ = 0.00–0.20 slight agreement; κ = 0.21–
0.40 fair agreement; κ = 0.41–0.60 moderate agreement;
κ = 0.61–0.80 substantial agreement; κ = 0.81–1.00 almost
perfect agreement [37]. The McNemar test was used to
test for the null hypothesis that there was no concordance
between the two methods. All probabilities were 2-tailed,
and P values <.05 were considered statistically signiﬁcant.
Statistical calculations were performed with the R statistical
software package.
3. Results
3.1. Real-Time Quantitative Methylation-Speciﬁc PCR
(QMSP) is a Sensitive and Speciﬁc Method to Determine


























Figure 1: Box plot for the MGMT/ACTB ratios determined by
Quantitative Methylatiom Speciﬁc PCR in normal brain tissues and
tumour samples. NBT: Normal brain tissues (n = 28); FFPE:
Formalin ﬁxed paraﬃn-embedded samples (n = 28); SnF: Snap-
frozen specimens (n = 2 2 ) ;T u m :T o t a lt u m o u rs a m p l e s( n = 50).
The boxes mark the interquartile range, (interval between the 25th
and 75th percentile). The lines inside the boxes denote median
values. The whiskers represent the interval between the 10th and
90th percentiles. ∗indicates the extreme cases with more than three
boxes length upper or down from the interquartile range.
MGMT Methylation Status in Gliomas. DNA from 50 brain
tumours (28 FFPE samples and 22 snap-frozen specimens)
and 28 normal brain tissues obtained from autopsies were
analyzed by QMSP assay to determine MGMT promoter
methylation status. For each sample the analysis was
repeated in three separate plates and the median value of the
MGMT/ACTB ratioofthethreeplateswasusedforstatistical
analyses. The median MGMT/ACTB ratios for the negative
a n dp o s i t i v ec o n t r o l su s e di ne a c hP C Rr e a c t i o n( at o t a lo f2 0
determinations) were as follows: unmethylated DNA median
MGMT/ACTB ratio 0 (IQR 0-0) and methylated DNA
median MGMT/ACTB ratio 710.64 (IQR 562.80–933.00)
(Figure 1).
The median values and Interquartile ranges (IQRs) of
MGMT/ACBT ratios for the three type of sample groups
were as follows: 0 (IQR 0–0.019) for the normal brain
tissue group, 1.16 (IQR 0–34.27) for FFPE, and 5.98 (IQR
0–70.46) for snap-frozen specimens (P<. 0007 Kruskall
Wallis) (Figure 1). The Dunn test demonstrated statistically
signiﬁcant diﬀerences between healthy controls and both
FFPE (P<. 01) and snap-frozen (P<. 01) specimens
groups, but no statistically signiﬁcant diﬀerence was found
when FFPE and snap-frozen samples groups were compared.
The statistically signiﬁcant diﬀerence with the normal brain
tissue group was maintained when FFPE and fresh-frozen
specimens were considered as one group with a median
MGMT/ACTB ratio of 2.48 (IQR 0–50.39) (P<. 000009
Mann-Whitney Test).
The MGMT/ACTB ratios in the normal brain tissues
and in tumour samples were used to draw an ROC curve
(Figure 2(a)), the AUC value of the curve was 0.75 (P<
.000001). Based on the ROC curve an optimal cutoﬀ value of4 Journal of Biomedicine and Biotechnology
0.35yieldeda58%(95%CI:45%–71%)sensitivityanda93%
(95%CI:84%–100%)speciﬁcity.ComparisonofROCcurves
construed by considering FFPE and snap-frozen specimens
as separate groups indicate that the test performs better on
frozen specimens (AUC 0.80; P = .0000001) than on FFPE
samples (AUC 0.71; P = .001) but this diﬀerence was not
statistically signiﬁcant (P = .26) (Figure 2(b)).
As shown in Figure 2(c) the majority of tumour samples
showed methylation levels well above the cutoﬀ value of
0.35. When compared with the normal brain tissue group
(Table 1), methylation frequencies determined by QMSP
were signiﬁcantly diﬀerent for FFPE (P = .000009, Z-
test), snap-frozen specimens (P = .000001, Z-test) as well
as for the two groups combined (P = .0000007, Z-test),
whereas no statistically signiﬁcant diﬀerence was demon-
strated between the FFPE and the snap-frozen groups. In the
three patients for which metachrone lesions were available,
G3 showed methylation in the primary tumour and in the
two recurrences, G8 did not show methylation in either the
p r i m a ryt u m o u ro rr e c u r r e n c e ,w h e r e a sf o rG 2 4m e t h y l a t i o n
was detected in the recurrence but not in the primary
glioblastoma (Table 2). Methylation levels above the cutoﬀ
value of 0.35 were detected in 24 glioblastoma multiforme
samples (48% of the tumours analyzed), 3 astrocytomas (6%
of the tumour analyzed), and 2 oligodendrogliomas (4% of
the tumour analyzed).
3.2. Determination of MGMT Status by Methylation-Speciﬁc
PCR (MSP). Methylation frequencies determined by MSP
are shown in Table 1. The overall sensitivity and speciﬁcity
of the assay were, respectively, 56% (95%CI: 42%–70%)
and 64% (95%CI: 46%–82%). A statistically signiﬁcant
diﬀerence in methylation frequencies was found between
the normal brain tissue group and the two tumour groups
combined (P = .04 Z-test). However, when the tumour
groups were considered separately, MSP analysis was able
to demonstrate statistical signiﬁcant diﬀerences with the
normal brain tissue group only for the fresh frozen specimen
group (P = .01 Z-test) but not for the FFPE specimen group
(P = .21 Z-test) (Table 1).
3.3. QMSPisMoreSpeciﬁc ThanMSP inDeterminingMGMT
Methylation Status in Gliomas. When promoter methylation
frequencies determined by MSP and QMSP were compared,
no diﬀerences were demonstrated for tumour groups but a
statistically signiﬁcant diﬀerence was found in the normal
brain tissue group (P = .005 Proportions’ Diﬀerence Z-
Test) (Table 1). The measurement of the degree of agreement
between the two technique demonstrated a good concor-
dance in tumour samples considered as a separate groups or
combined in one group, whereas the agreement was poor in
the normal brain sample group (Table 3).
In the normal brain tissue group, 8 out of the 10 cases
positive by MSP displayed MGMT/ACTB ratios below the
0.35 cutoﬀ value by QMSP (Figure 3). In FFPE samples
QMSP as compared with MSP detected two additional
positive (G17 median 3.35, IQR 2.81–3.89 and G22 median
0.35, IQR 0.24–0.46) (Figure 3). In snap-frozen specimens,





















































































Figure 2: ROC curve analysis of Quantitative Methylation-speciﬁc
PCR results. (a) ROC curve for QMSP assay was designed on the
basis of MGMT/ACTB ratios in determined in normal brain tissues
(n = 28) and total tumour samples (n = 50). The area under the
curve (AUC) is 0.74 (P = .000001). (b) Comparison of ROC curves
were designed on the basis of MGMT/ACTB ratios determined
in normal brain tissues (n = 28) and FFPE (n = 28) or snap-
frozen specimens (n = 22). The area under the curve (AUC) is
0.70 (P = .001) for FFPE samples and 0.79 (P = .0000001)
for snap-frozen specimens. (c) Scatter plot in logarithm scale of
MGMT/ACTB ratios in normal brain tissue (NBT), tumour FFPE
samples, and snap-frozen (SnF) specimens. ∗indicates samples with
an MGMT/ACTB ratio of 0 which cannot be plotted on a logarithm
scale (n = 21 for NBT, n = 13 for FFPE and n = 6f o rS n F ) .T h e
horizontal line indicates the optimal cutoﬀ value of 0.35.Journal of Biomedicine and Biotechnology 5
Table 1: MGMT methylation frequencies in normal brain tissues and glioma samples.
MGMT ∗ status Normal brain tissues n = 28 FFPE samples# n = 28 Frozen samples n = 22 Total tumour samples n = 50
QMSP MSP QMSP MSP QMSP MSP QMSP MSP
neg 26 (92.9%) 18 (64.3%) 13 (46.4%) 15 (53.6%) 8 (36.4%) 7 (31.8%) 21 (42.0%) 22 (44.0%)
pos 2 (7.1%) 10 (35.7%) 15 (53.6%) 13 (46.4%) 14 (63.6%) 15 (68.2%) 29 (58.0%) 28 (56.0%)
∗neg: Methylation levels for QMSP are below the cutoﬀ point of 0.35, no band is seen in gel electrophoresis for MSP; pos: Methylation levels for QMSP exceed
the cutoﬀ point of 0.35, a band is seen in gel electrophoresis for MSP.
# FFPE: Formalin-ﬁxed paraﬃn-embedded.
Table 2: MGMT promoter methylation status in primary tumour and recurrences by quantitative methylation-speciﬁc PCR (QMSP) and
Methylation-Speciﬁc PCR (MSP).




GB 0 FFPE 28.41 13.28–47.82 pos pos
GB 28 FFPE 12.8 11.07–16.00 pos pos
GB 29 FFPE 209.37 101.70–226.68 pos pos
G8 GB 0 FFPE 0 0-0 neg neg
GB 10 FFPE 0 0-0 neg neg
G24 GB 0 FFPE 0 0-0 neg neg
GB 9 SF 5.98 4.37–7.60 pos pos
∗GB: Glioblastoma.
§number of months from ﬁrst surgery.
# FFPE: Formalin ﬁxed paraﬃn-embedded sample; SF: Snap-frozen pecimen.
¶ IQR: Interquartile range; pos: Methylation levels for QMSP exceed the cutoﬀ point of 0.35, a band is seen in gel electrophoresis for MSP; neg: Methylation
levels for QMSP are below the cutoﬀ point of 0.35, no band is seen in gel electrophoresis for MSP.
t h r e ec a s e sw e r ep o s i t i v ea tM S Pb u tn o ta tQ M S P( G 3 4
median 0.01, IQR 0–0.04; G35 median 0.03, IQR 0–0.18;
G42 median 0, IQR 0-0), whereas two cases were negative
at MSP and positive at QMSP (G39 median 1.39, IQR 1.30–
1.50 and G45 median 2.48, IQR 2.03–2.93) (Figure 3). The
analysis of methylation status in the three patients for which
primarytumourandrecurrenceswereavailableshowedMSP
and QMSP analyses concordant results (Table 2, Figure 3).
4. Discussion
Determination of MGMT promoter methylation status is
likely to become a pivotal tool in the management of
chemotherapy in glioma patients [7]. Thus there is the
need for sensitive and speciﬁc diagnostic tools that can be
easily implemented into the clinical setting. In this study
we applied real-time Quantitative Methylation-Speciﬁc PCR
(QMSP) analysis to determine MGMT methylation status in
as e r i e so fp a r a ﬃn-embedded and fresh frozen specimens
from glioma patients. As compared with the real-time-
based MSP approach recently described by Vlassenbroeck
et al. [30] the speciﬁcity of our assay was evaluated by
determining methylation status in 28 normal brain tissues
obtained from autopsies. Very low levels of methylation were
detected in normal brain whereas MGMT/ACTB ratios were
signiﬁcantly higher in tumours. The ROC curve construed
by using the MGMT/ACTB ratios in normal brain tissues
and tumour samples allowed the deﬁnition of an optimal
cutoﬀ value of 0.35, which yielded a 93% (95%CI: 84%–
100%) speciﬁcity and a 58% (95%CI: 45%–71%) sensitivity.
As expected the comparison of ROC curves indicate that
the test performs better on snap-frozen specimens than on
FFPE samples, however this diﬀerence was not statistically
signiﬁcant suggesting that QMSP could be a reliable method
to determine methylation status in the clinical setting.
Although a 58% sensitivity may seem too low for clinical
testing it has to be considered that MGMT analysis is a
predictive and not a diagnostic tool. MGMT methylation
is reported in approximately one half of the glioblastoma
samples thus our results are consistent with published data
[5, 7] The analysis of our normal and tumour samples by
conventional MSP with the same primer set used for QMSP
showed a similar sensitivity (56%; 95%CI: 42%–70%) but a
much lower speciﬁcity (64%; 95%CI: 46%–82%).
While on tumour tissues QMSP and MSP showed a
good concordance, results on normal brain tissues indicate
a poor agreement. A faint shadow band was observed on gel
electrophoresis of MSP analysis in 8 normal brain tissues. In
all these instances methylation levels determined by QMSP
were negative or well below the cutoﬀ value, suggesting
that conventional MSP bears a higher risk of false positive
results as compared with QMSP. This leads us to speculate
that the three tumour samples showing faint bands on gel
electrophoresis by MSP but MGMT/ACTB ratios below the
cutoﬀ value are likely to represent false positive results that
wouldwronglyclassifythepatientsasrespondertoalkylating
agents chemotherapy. Four glioma samples were negative by
MSP but displayed MGMT/ACTB ratios above (G17, G39,
and G45) or equal (G22) to the cutoﬀ value. These data
suggest that on larger sample cohorts QMSP analysis could6 Journal of Biomedicine and Biotechnology
Table 3: Comparison of MGMT methylation status as determined by Quantitative Methylation-Speciﬁc PCR (QMSP) and. Methylation-
Speciﬁc PCR (MSP).
NBT∗n = 28 FFPE∗n = 28 SF∗n = 22 Tumours∗n = 50 Total samples∗n = 78
MSP + MSP- MSP + MSP- MSP + MSP- MSP + MSP- MSP + MSP-
QMSP <0.35 81 801 33 5 3 1 8 1 1 3 6
>0.35 2 0 13 2 12 2 25 4 27 4
κ# 0.243 0.860 0.495 0.715 0.613
95%CI 0.084–0.40 0.73–0.99 0.286–0.704 0.59–0.84 0.505–0.712
P .049 P<. 0001 P = .00195 <.0001 <.0001
∗ NBT: Normal brain tissue; FFPE: Formalin ﬁxed paraﬃn embedded specimens, SF: Snap-frozen specimen; MSP +: A band is seen in gel electrophoresis; -:
No band is seen in gel electrophoresis.
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Figure 3: Comparison of QMSP analysis MSP . Representative results of Methylation-Speciﬁc PCR analysis and comparison with
Quantitative Methylation-Speciﬁc PCR. As control of the bisulphite conversion the upper panels show PCR reactions speciﬁc for the ACTB
gene promoter region not containing CpG; the middle panels show PCR reactions speciﬁc for the methylated sequence of the MGMT
promoter; lower panels show results of QMSP. MW: Molecular weight marker. M, positive control (CpGenome Universal Methylated DNA);
UM: Negative control (Universal Unmethylated DNA); N: Normal brain tissue; G: Glioma sample. Normal brain tissues N4, N7, N26 and
snap-frozentumoursampleG43showfaintbandsinthegelelectrophoresisbutMGMT/ACTB ratiosbelowthecutoﬀvalueof0.35byQMSP,
snap-frozen sample G45 show no methylated band by MSP but an MGMT/ACTB ratio above the cutoﬀ value of 0.35 by QPCR.
be also more sensitive than MSP in the determination of
MGMT methylation status.
5. Conclusions
QMSP combines the advantages of MSP (high sensitivity,
applicability to any CpGs) [12] and real-time PCR (rapidity,
small quantity of starting DNA, large dynamic range)
[26]. Moreover our results indicate that QMSP is more
speciﬁc than MSP in the determination of MGMT status in
gliomas. The robustness of QMSP analysis was conﬁrmed
on FFPE samples which makes it possible to investigate
MGMT promoter methylation of archival tissues in a cost
eﬃcientandaccurateway.Ascomparedtoothermethodsfor
aberrant promoter methylation analysis, QMSP is deﬁnitely
less labour-intensive and time-consuming than bisulphite
sequencing and COBRA analysis and does not require costly
dedicated equipments as for Pyrosequencing and MALDI-
TOF [15, 16, 38, 39]. In addition QMSP analysis is suitable
for large-scale applications and may catalyze the widespread
use of MGMT analysis into clinical practice.
Nonstandard Abbreviations
QMSP: Quantitative methylation-speciﬁc PCR
MSP: Methylation-speciﬁc PCR
FFPE: Formal-ﬁxed paraﬃn-embedded
ROC: Receiver operating characteristic
AUC: Area under curve.Journal of Biomedicine and Biotechnology 7
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